Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Hepatoblastoma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Malignant Peripheral Nerve Sheath Tumors 1Ototoxicity 1Oligodendroglioma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Azacitidine 26venetoclax 20Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 13Biopsy 13fludarabine 12Specimen Handling 12Tacrolimus 11Mycophenolic Acid 11Decitabine 10Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 9Injections 8Cytarabine 8Busulfan 8decitabine and cedazuridine drug combination 7Melphalan 7X-Rays 5Hematopoietic Stem Cell Transplantation 5Cyclosporine 5Sirolimus 4ruxolitinib 3olutasidenib 3enasidenib 3cedazuridine 3Magnetic Resonance Spectroscopy 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Vorinostat × 1 year × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡